Methodology The central radiotherapy prescribing system at a single institution was interrogated to identify patients with locally advanced cervical cancer who received SBRT boost to cervix in addition to or as a replacement for IBGT, from 1st July 2017 to 31st January 2021.

Results 17 patients were identified; median age was 68 years (range 32–77) and median follow up was 17 months. FIGO 2009 stage distribution was II (8/17), III (7/17), and IV (2/17). Mean tumour size was 4.5 cm. Indication for SBRT consisted of: medical contra-indication (9/17), unfavourable anatomy (5/17), and patient refusal (3/17). Median dose of external beam was 45 Gy in 25 fractions (range 43–50 Gy). SBRT boost PTV was delineated on CT (cervix and gross residual disease with a 4–5-mm margin), aiming for 24–28 Gy in 4 fractions (range 7–28 Gy). Mean cumulative EQD2 (α/β= 10) was 75.2 Gy (range 58–91), and median SBRT PTV size was 54 cm³ (range 12–126). Local control rate was 15/17 (88.2%). G3 toxicity occurred in 2/17 (11.8%); one rectovaginal-vaginal and one vesico-vaginal fistula (the latter had progressive disease). No G4–5 toxicity was reported.

Conclusion SBRT boost was effective and tolerable in this cohort, but EQD2 of 85–90 Gy was not achieved in majority of cases. MRI based planning may improve target delineation and a consensus guideline on appropriate constraints would be advantageous.

2022-RA-729-ESGO STRENGTHENING OF PELVIC FLOOR MUSCLES FOR INCONTINENCE IN CERVICAL CANCER

Introduction/Background Objective to analyze the effect of pelvic floor muscle strengthening exercises on urinary incontinence in patients with cervical cancer.

Methodology This study included 45 cervical cancer patients undergoing radiation therapy by using non-probability convenience sampling technique and design as quasi-experimental one-group pre-post design. Intervention consisted of four pelvic floor exercises. The patient was assessed for urinary incontinence by using the ICIQ UI-SF tool and perineometer on the 8th and 12th weeks. The statistical evaluation plan was the demographic and clinical data summarized with descriptive statistics and primary objectives evaluated with Friedman test, one-way ANOVA test and secondary objectives were evaluated with frequency distribution and chi-square test.

Results In this study 45 women received the intervention. The result showed the frequency, quantity of urinary incontinence significantly reduced from the patient’s baseline parameters. Participant’s ICIQ UI-SF total score was observed that on pre-test mean 12.56 (SD±3.74), 8 weeks of intervention mean 11.33 (SD±3.48) and 12 weeks of intervention mean 8.86 (SD±2.97) and P-value was statistically significant (p <0.001). There was a significant (P <0.001) improvement in the quality of life of participants. The research hypothesis was accepted. There was significant (p < 0.001) alleviation in urinary incontinence after pelvic floor muscle strengthening exercises in a patient with cervical cancer undergoing radiation therapy. The pelvic floor muscle contractility on perineometer on pre-intervention mean was 21.63 (SD±2.71), on post-intervention 8 weeks mean was 22.33 (SD±2.65) and 12 weeks mean was 23.49 (SD±2.16). The pelvic floor muscle strengthening exercises were statistically significant (p < 0.001).

Conclusion Pelvic floor muscle strengthening exercises were effective for alleviating urinary incontinence which improved the quality of life of patients with cervical cancer undergoing radiation therapy. It is a statistically significant intervention.

2022-RA-733-ESGO DURATION OF HPV PERSISTENCE AND ITS RELATIONSHIP WITH RECURRENT CERVICAL DYSPLASIA

Giuseppe Capalbo,1 Violante Di Donato,2 Francesco Soprano,2 In Andrea Ciavattini,1 Benito Chiocchio,1 Enrico Vizza,1 Paolo Verellini,2 Fabio Ghezzi,1 Giovanni Scambia,1 Francesco Raspagliesi,1 Innocenza Palia,1 Gianfranco Petruzzelli,2 Ludovico Muzzi,1 Giorgio Bogani,1 Department of Gynecological, Obstetrical and Urological Sciences, Sapienza University of Rome, Rome, Italy;1 Department of Gynecological, Obstetrical and Urological Sciences, Sapienza University of Rome, Rome, Italy;1 Gynecological Oncology Unit, Centro di Riferimento Oncologico – National Cancer Institute, Aviano, Italy;1 Woman’s Health Sciences Department, Gynecologic Section, Polytechnic University of Marche, Ancona, Italy;1 Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy;1 Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute., Rome, Italy;1 Gynecology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;1 Department of Obstetrics and Gynecology, ‘Filippo del Ponte’ Hospital, University of Insubria, Ospedale di circolo Fondazione Macchi, Varese, Italy, Varese, Italy;1 UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubb, Fondazione Politecnico Universitario A. Gemelli, IRCCS, Roma, Italy; Rome, Italy;1 Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy;1 Department of Gynecological, Obstetrical and Urological Sciences, Sapienza University of Rome, Rome, Italy.

Introduction/Background HPV persistence after conization represent one of the most important risk factors for disease recurrence. However, no data regarding the impact of duration of HPV persistence are still available. Here, we aim to evaluate the how duration of HPV persistence influence the risk of developing recurrent high-grade cervical dysplasia (CIN2+).

Methodology Data of patients with persistent HPV infection (at least at 6 months) after primary conization were extracted from a multi-institutional Italian database, retrospectively. Kaplan-Meier and Cox proportional hazards models were used to evaluate associations between duration of HPV persistence with the 5-year risk of developing recurrent CIN2+. Results Overall, 545 patients met the inclusion criteria. Positive margins were detected in 160 (29.3%) patients. Overall, 247 (45.3%) and 123 (22.6%) patients had a documented infection from HPV16/18, and other HR-HPV types. 187 (34.3%), 73 (13.4%), and 40 (7.3%) were diagnosed with persistent HPV infection at 12-, 18-, and 24-month, respectively. Patients with HPV persistence at 6-month experienced a risk of recurrence of 7.46%. Twelve-month HPV persistence strongly correlates with the risk of developing the recurrent...